Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2026-01-22 @ 6:10 AM
Study NCT ID:
NCT03575234
Status:
WITHDRAWN
Last Update Posted:
2019-08-28
First Post:
2018-06-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Sponsor:
Emory University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | View |
| None | Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and … | View |
| None | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and … | View |
| None | Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and … | View |
| None | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | View |
Keywords: